|Gefen Biomed Investments Ltd -- Israel Stock|| |
ILS 4.8 0.00 0.00%
Dr. BenZion Weiner serves as Director at Gefen Biomed Investments Ltd since Aug. 9, 2010. In January 2006, Dr. Weiner became Chief RD Officer
Age: 71 Director Since 2010
972 8 675 1122 http://www.gefenbiomed.com
Weiner was Vice PresidentGlobal Products from April 2002 until January 2006, and Vice PresidentResearch and Development from 1986, to 2002. In 1975, Dr. Weiner received a Ph.D. in Chemistry from the Hebrew University of Jerusalem, where he also received BSc and MSc degrees. He conducted his postdoctorate research at ScheringPlough Corporationrationrationration in the United States. He was granted the Rothschild Prize for Innovation and Export twice, in 1989, for the development of Alpha D3 for dialysis and osteoporosis patients and in 1999, for the development of Copaxone for multiple sclerosis.
The company has return on total asset (ROA)
of 20.33 %
which means that it generated profit of $20.33 on every $100 spent on asset. This is normal as compared to the sector avarege.
The company has accumulated 20.23 M in total debt with debt to equity ratio (D/E) of 0.49 which is about average as compared to similar companies. Gefen Biomed Investments Ltd has Current Ratio of 0.58 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
Gefen Biomed Investments Ltd engages in the location, screening, and investment in earlystage medical devices and biotechnology companies. Gefen Biomed Investments Ltd (GEFEN) is traded on Tel Aviv Stock Exchange in Israel. It is located in Ashkelon, and employs 12 people.